Tuberculosis and its future management
| Autor: | John C Moore-Gillon |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Tuberculosis business.industry media_common.quotation_subject Public health Antitubercular Agents Developing country medicine.disease Surgery Editorial Acquired immunodeficiency syndrome (AIDS) Family medicine BCG Vaccine medicine Humans Prosperity business Tuberculosis Pulmonary Developed country BCG vaccine Forecasting Pharmaceutical industry media_common |
| Zdroj: | Thorax. 62:1019-1021 |
| ISSN: | 0040-6376 |
| Popis: | Will we do better in the next 25 years? Twenty-five years ago, most writers on tuberculosis (TB) would, if asked to predict what the position would be by 2007, have anticipated better diagnostics, safer drugs, shorter treatment times, a better vaccine, the near eradication of TB in the developed world and falling rates in the developing world. Some perceptive individuals were sounding the warning bells, but most pundits would have been profoundly wrong. They would have been closest to the mark if they had simply summed up their prediction of the position 25 years later, in 2007, as “Much the same, really—except where it’s much worse.” Predictions about TB are particularly fraught with difficulty because the impact of factors beyond the control of clinicians, researchers and the pharmaceutical industry is far greater with TB than it is in diseases like asthma, chronic obstructive pulmonary disease and lung cancer. These views on TB and its future management are therefore contingent upon three assumptions—all, some or none of which may come to pass: a modest increase in overall global prosperity, wars and political instability being at least no worse than they are at present, and the development of a reasonably effective AIDS vaccine. We can be completely confident of only one thing: 25 years from now, the December 2032 issue of Thorax (whether on paper or not) will reproduce these December 2007 editorials with a commentary on the extent to which I (and my co-authors) got it wrong. The Stop TB partnership, coordinated by the World Health Organisation, has set out the actions—and the funds—needed for TB control.1 Targets include the halving, by 2015, of TB prevalence and deaths compared with 1990 levels, and the elimination of TB as a global public health problem by 2050. Progress in vaccines, … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|